Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer.

ABSTRACT:

Aim

It is important to identify anti-cancer compounds that can inhibit specific molecular targets to eradicate androgen-receptor negative (AR^neg), androgen-independent (AI) prostate cancer, which is an aggressive form of prostate cancer with limited treatment options. The goal of this study was to selectively target prostate cancer cells that have high levels of oncogenic protein Receptor tyrosine kinase-like orphan receptor 1 (ROR1) by using strictinin, a small molecule ROR1 inhibitor.

Methods

The methods performed in this study include western blots, methyl thiazolyl tetrazolium (MTT) proliferation assays, phosphatidylserine apoptosis assays, apoptosis flow cytometry (Annexin V, caspase 3/7), migration scratch assays, Boyden chamber invasion assays, and cell cyc

SUBMITTER: Sivaganesh V 

PROVIDER: S-EPMC10784114 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature